grazoprevir + ribavirin

Grazoprevir + ribavirin is an *experimental antiviral drug combination* studied for the treatment of chronic hepatitis C virus (HCV) infection, particularly certain genotypes. Grazoprevir is a second-generation hepatitis C virus NS3/4A protease inhibitor, and ribavirin is a nucleoside analog with broad-spectrum antiviral activity. This combination has been studied with or without additional agents (e.g., elbasvir) for efficacy against HCV genotypes 2, 4, 5, and 6. While grazoprevir + ribavirin alone showed some efficacy in clinical studies (e.g., about 67% SVR12 for genotype 2 in the C-SCAPE trial), it is primarily used within triple combinations for better efficacy, and not widely adopted as a standard dual therapy. The combination works by both inhibiting viral protease activity (grazoprevir) and inducing lethal mutagenesis (ribavirin), suppressing viral replication by separate mechanisms[2].